-
Capital, M&A & Industry Strategy1 month agoNovo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
Novo has struck a 1.17 billion euro ($1.3 billion) deal to combine Nanexa’s long-acting injectable drug delivery platform with its obesity and Type 2 diabetes drugs.
-
Capital, M&A & Industry Strategy1 month agoADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.
-
Capital, M&A & Industry Strategy1 month agoRNAi drug specialist ADARx raises $446M IPO
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in...
-
Capital, M&A & Industry Strategy1 month agoEnveda’s latest megaround puts $311M behind AI push: Venture Report
BIOCENTURY | FINANCEENVEDA’S LATEST MEGAROUND PUTS $311M BEHIND AI PUSH: VENTURE REPORTPlus: Basecamp readies for its next climb with $140M round; Finland’s Kasvu draws €30M for antidepressant;...
-
Capital, M&A & Industry Strategy1 month agoRoche inks up to $2B deal with Atavistik for new cardiometabolic drugs
The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases.
-
Capital, M&A & Industry Strategy1 month agoLilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia...
-
Capital, M&A & Industry Strategy1 month agoLilly forges $3.35bn alliance with China’s InnoCare
Eli Lilly continues a busy period of deal-making with a five-project partnership with InnoCare that includes $100m in upfront and near-term payments.
-
Capital, M&A & Industry Strategy1 month agoSTAT+: Why Gilead can’t stop talking about its ambitions in immunology
Gilead Sciences’ top executives have been emphatically bullish about the biotech’s years-long push to develop drugs for inflammatory and autoimmune diseases.
-
Capital, M&A & Industry Strategy1 month agoChina’s Henlius carves out $440M T-cell engager deal with Amberstone
Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers.
-
Capital, M&A & Industry Strategy1 month agoBasecamp Research secures $140m for AI-driven therapies
S32 led the oversubscribed financing round. Investors included Catalio Capital Management, European Tech Collective, and Firebrand River Capital. Other backers were Nvidia, PostScriptum, Redalpine, The Rockefeller...
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
